| Dr Joseph Frank Gerace, DO | |
|
80 Seymour St, Dept. Of Anesthesia, Hartford, CT 06102-5037 | |
| (860) 282-4022 | |
| (860) 282-0834 |
| Full Name | Dr Joseph Frank Gerace |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 23 Years |
| Location | 80 Seymour St, Hartford, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184663353 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 047317 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| John Dempsey Hospital | Farmington, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Integrated Anesthesia Associates Llc | 1759281165 | 373 |
News Archive
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for under-served medical needs in neurology and cardiology, announced the completion of the interim analysis of the pivotal efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy (SMA).
The Affordable Care Act - or Obamacare - most benefited those closest to the federal poverty line, a study led by Drexel University researchers shows.
In a new study NYU School of Medicine researchers report that they have found several chemical compounds, including an antidepressant, that have powerful effects against brain-destroying prion infections in mice, opening the door to potential treatments for human prion diseases.
NUCRYST Pharmaceuticals, a developer and manufacturer of medical products that fight infection and inflammation, today announced that on September 15, 2009 it received notice from the Nasdaq Stock Market that it no longer complies with Nasdaq Marketplace Rule 5550(a)(2) because, for the previous 30 consecutive business days, the bid price of its common stock had closed below the minimum requirement of $1.00 per share.
› Verified 9 days ago
| Entity Name | Integrated Anesthesia Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881636397 PECOS PAC ID: 1759281165 Enrollment ID: O20040112000163 |
News Archive
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for under-served medical needs in neurology and cardiology, announced the completion of the interim analysis of the pivotal efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy (SMA).
The Affordable Care Act - or Obamacare - most benefited those closest to the federal poverty line, a study led by Drexel University researchers shows.
In a new study NYU School of Medicine researchers report that they have found several chemical compounds, including an antidepressant, that have powerful effects against brain-destroying prion infections in mice, opening the door to potential treatments for human prion diseases.
NUCRYST Pharmaceuticals, a developer and manufacturer of medical products that fight infection and inflammation, today announced that on September 15, 2009 it received notice from the Nasdaq Stock Market that it no longer complies with Nasdaq Marketplace Rule 5550(a)(2) because, for the previous 30 consecutive business days, the bid price of its common stock had closed below the minimum requirement of $1.00 per share.
› Verified 9 days ago
| Entity Name | Uconn Health Center Anesthesiology |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710937172 PECOS PAC ID: 2466349667 Enrollment ID: O20040302001136 |
News Archive
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for under-served medical needs in neurology and cardiology, announced the completion of the interim analysis of the pivotal efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy (SMA).
The Affordable Care Act - or Obamacare - most benefited those closest to the federal poverty line, a study led by Drexel University researchers shows.
In a new study NYU School of Medicine researchers report that they have found several chemical compounds, including an antidepressant, that have powerful effects against brain-destroying prion infections in mice, opening the door to potential treatments for human prion diseases.
NUCRYST Pharmaceuticals, a developer and manufacturer of medical products that fight infection and inflammation, today announced that on September 15, 2009 it received notice from the Nasdaq Stock Market that it no longer complies with Nasdaq Marketplace Rule 5550(a)(2) because, for the previous 30 consecutive business days, the bid price of its common stock had closed below the minimum requirement of $1.00 per share.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joseph Frank Gerace, DO 99 East River Drive, 5th Floor, East Hartford, CT 06108 Ph: (860) 282-0833 | Dr Joseph Frank Gerace, DO 80 Seymour St, Dept. Of Anesthesia, Hartford, CT 06102-5037 Ph: (860) 282-4022 |
News Archive
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for under-served medical needs in neurology and cardiology, announced the completion of the interim analysis of the pivotal efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy (SMA).
The Affordable Care Act - or Obamacare - most benefited those closest to the federal poverty line, a study led by Drexel University researchers shows.
In a new study NYU School of Medicine researchers report that they have found several chemical compounds, including an antidepressant, that have powerful effects against brain-destroying prion infections in mice, opening the door to potential treatments for human prion diseases.
NUCRYST Pharmaceuticals, a developer and manufacturer of medical products that fight infection and inflammation, today announced that on September 15, 2009 it received notice from the Nasdaq Stock Market that it no longer complies with Nasdaq Marketplace Rule 5550(a)(2) because, for the previous 30 consecutive business days, the bid price of its common stock had closed below the minimum requirement of $1.00 per share.
› Verified 9 days ago
Phillip Dennen, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 114 Woodland St, Hartford, CT 06105 Phone: 860-714-6654 Fax: 860-714-8110 | |
Frank J Setter, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 114 Woodland St, Hartford, CT 06105 Phone: 860-714-6654 Fax: 860-714-8110 | |
Nitish Gupta, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 80 Seymour St, Hartford, CT 06106 Phone: 860-545-5000 | |
Adam Jason Sachs, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 80 Seymour St, Hartford, CT 06102 Phone: 516-521-8645 | |
Ethan Kim, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 80 Seymour St, Hartford, CT 06106 Phone: 860-545-5000 | |
Roxanne Zarmsky, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 114 Woodland St, Hartford, CT 06105 Phone: 860-714-6654 Fax: 860-714-8110 | |
Dr. Saadia Zafar, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 114 Woodland St, Hartford, CT 06105 Phone: 860-714-6654 |